About Us

Innovation in Biotechnology for Biomedical Research

About Us

In RareBioTech, as a biotechnology company, we develop advanced biotechnological solutions to overcome the challenges of biomedical research. Our optimized protocols and customized solutions enable researchers, clinicians, and pharmaceutical companies to advance precision medicine with greater speed and efficiency. Our mission is to shorten the path from discovery to cure, supporting translational biomedicine and bridging the gap between academic research and the real needs of basic, applied, and translational laboratories to advance the understanding of diseases.

How shall we proceed?

Investigadores en laboratorio de RareBioTech generando lentivirus con tecnología de vanguardia para terapia génica y biotecnología avanzada.

Cutting-Edge Technology

As a biotechnology company, we generate High-capacity lentivirus (up to 20 kb), surpassing the traditional limitations for the study of complex genes.

Innovación Responsable en medicina de precisión: protocolos optimizados y soluciones personalizadas para investigadores, médicos y farmacéuticas

Responsible Innovation

Our optimized protocols and tailored solutions they enable researchers, clinicians, and pharmaceutical companies to advance in precision medicine with greater speed and efficiency.

Innovación Responsable en medicina de precisión: protocolos optimizados y soluciones personalizadas para investigadores, médicos y farmacéuticas.

Focus on the Urgent

Prioritizing rare diseases, our biotechnology company offers technical solutions and specialized support to drive projects with real impact.

Team and Collaborations

At RareBioTech we combine academic rigor with business agility to develop biotechnological solutions. We are spin-off from GIRBER-USAL (Research Group in Biomedicine of Rare Diseases at the University of Salamanca), which enables us to:

  • Access to cutting-edge knowledge and methodologies validated in elite scientific environments.

  • Efficient Technology Transfer, bringing laboratory discoveries to the market with ethical standards

Our work is supported by leading academic and technological authorities, as well as by an international network of scientific collaborations.

Girber - Grupo de Investigación en Biomedicina de Enfermedades Raras de la Universidad de Salamanca
universidad_de_salamanca
Ayuntamiento-de-Salamanca

Awards and Recognitions

2025

  • 14 NOVEMBER – Award Innovation in 5P Digital Medicine

RareBioTech S.L. is proud to have received the award for Maximum Innovation Potential at the EU Demo Day InnoMedCatalyst held in Bologna (14/11/2025). This prestigious recognition boosts our mission to develop groundbreaking solutions that transform precision medicine and contribute to a more predictive, personalized, and accurate healthcare future.. More information

    • 20 May – Granting of use of ABIOINNOVA spaces

    RareBiotech obtained direct authorisation to establish itself in the high-tech biomedical and biotechnology incubator of Salamanca City Council. More information

      • 25–27 JUNE – Participation in Salamanca Tech Summit

      Presentation of RareBiotech as a success story within the ABIOINNOVA ecosystem, at the Salamanca Conference Centre. More information

        • JULY – BETA Programme Support (USAL)

        RareBiotech has been awarded a grant from the BETA In-House Programme of the University of Salamanca (USAL)an initiative aimed at boosting the creation of spin-offs and technology-based companies. This funding, granted within the framework of the TransferUSAL Plan 2025, recognises the innovative potential and the scientific-technical value of the RareBiotech project. The academic support is endorsed by the Prof. Dr. Jesús Lacal, coordinator responsible for the support, whose backing represents a strong institutional and scientific recognition. More information

        • JULY – Selected in the ITR Call of the TCUE Plan (USAL)

        RareBiotech has been selected in the ITR call (Itinerary for the Transfer of Results) of the TCUE Plan 2024–2027 of the University of Salamanca. This distinction includes funding to carry out a feasibility study and a exploitation plan with the support of a specialised consultancy, this is a key step in transferring research results to the market and advancing the consolidation of the RareBiotech project. More information

          • JULY – Selected for the InnoMedCatalyst Accelerator Programme

          RareBiotech has been one of the companies selected to participate in the InnoMedCatalyst Accelerator Programme, a European 8-week initiative focused on startups in MedTech and HealthTech specialising in digital precision medicine. This highly competitive programme offers personalised mentoring, training for investment acquisition, international visibility, and access to a network of experts and strategic partners.- The participation will culminate in a Demo Day in Bologna (Italy), where RareBiotech will have the opportunity to present its project to investors, institutions and potential European collaborators. More information

          • SEPTEMBER – Winning Application for the TCUE 2025 Plan

          RareBiotech has been selected winning application in the call for the Implementation of Proofs of Concept and Protection of Results from the University of Salamanca, within the TCUE Plan – 2025 Edition. This recognition includes support to technically validate the company’s developments and ensure their intellectual protection, a strategic step to strengthen market transfer and RareBiotech’s future competitiveness. More information

          en_GB
          es_ES en_GB